SEC Form 4 · accession 0001179110-17-003950
MADRIGAL PHARMACEUTICALS, INC. · MDGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc R Schneebaum
Officer — Chief Financial Officer
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 3:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157601
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.80 | Mar 2, 2017 | A | 27,300 | A | — | Mar 2, 2027 | Common Stock | 27,300 | 27,300 | D |
Explanation of responses
- F1The option vests as to 25% of the shares on the first anniversary of the date of grant (March 2, 2018) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date.